The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CSTL | +49.32% | -36.47% | -8.67% | +85% |
| S&P | +15.37% | +82.64% | +12.79% | +126% |
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
The genetic-testing company beat expectations with its Q2 results.
Insider selling by upper management sent the stock down for a fourth consecutive day.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $83.04M | -3.2% |
| Gross Profit | $61.53M | -8.7% |
| Gross Margin | 74.09% | -4.5% |
| Market Cap | $660.52M | -16.5% |
| Market Cap / Employee | $0.87M | 0.0% |
| Employees | 761 | 24.8% |
| Net Income | -$0.50M | -122.1% |
| EBITDA | -$2.99M | -134.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $85.56M | -9.9% |
| Accounts Receivable | $49.48M | -1.5% |
| Inventory | 8.7 | 31.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $35.69M | 42.8% |
| Short Term Debt | $1.45M | -17.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -2.27% | -3.5% |
| Return On Invested Capital | -7.33% | -0.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $7.80M | -54.0% |
| Operating Free Cash Flow | $22.63M | -3.0% |
| Metric | Q3 2024 | Q4 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 142.67 | 43.48 | - | ||
| Price to Book | 1.69 | 1.25 | 1.34 | 1.45 | -22.28% |
| Price to Sales | 2.42 | 1.65 | 1.74 | 1.93 | -28.33% |
| Price to Tangible Book Value | 2.26 | 1.63 | 1.63 | 1.88 | -26.06% |
| Price to Free Cash Flow TTM | 18.62 | 11.82 | 14.63 | 20.65 | -1.44% |
| Enterprise Value to EBITDA | 54.81 | 176.17 | -435.76 | -137.75 | -302.81% |
| Free Cash Flow Yield | 5.4% | 8.5% | 6.8% | 4.8% | 1.46% |
| Return on Equity | 4.3% | -1.2% | -2.2% | -2.7% | -283.39% |
| Total Debt | $26.45M | $25.84M | $37.35M | $37.14M | 38.89% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
